Resveratrol as a protective and ameliorative agent in endometriosis

Ameen Al-Salamy, Hasan Alghetaa
In: Journal of Endometriosis and Pelvic Pain Disorders · 2026 · doi:10.1177/22840265261438168 · W7160834151
article OA: closed CC0
View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-06 ⓘ

This review explores how resveratrol's anti-proliferative, anti-inflammatory, and hormone-modulating properties offer a non-hormonal therapeutic strategy for endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Endometriosis (END) is a gynecological disease marked by the presence of endometrial-like tissue outside the uterus, inducing estrogen-driven inflammation that manifests through chronic pelvic pain, dysmenorrhea, and infertility, which impacts life quality. The pathophysiology of END involves genetic factors, hormonal imbalances, and immune disorders, generating pro-angiogenic and inflammatory environment. Resveratrol (RES), a naturally occurring polyphenol, recently became known as a potential therapeutic product owing to its diverse biological functions. This review examines the pathophysiological origins of END and clarifies the processes by which RES has therapeutic benefits. Resveratrol offers a novel, non-hormonal treatment strategy for endometriosis management by exhibiting anti-proliferative, anti-invasive, anti-adhesive, pro-apoptotic, antioxidant, anti-inflammatory, anti-angiogenesis, and hormone-modulating properties.

My notes (saved in your browser only)

Condition tags

endometriosischronic_pelvic_paindysmenorrheainfertility

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Source provenance

openalex
last seen: 2026-06-14T06:02:12.833719+00:00
License: CC0 · commercial use OK